Cycloheximide
别名: NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80 中文名称：放线菌酮，环己酰亚胺
此产品请避光密封保存。
Cycloheximide (NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80)，一种抗真菌抗生素，是一种真核生物蛋白质合成（protein synthesis）抑制剂，对体内蛋白质合（protein synthesis）和 RNA 合成（RNA synthesis）的 IC50 分别为 532.5 nM 和 2880 nM。Cycloheximide抑制铁死亡并抑制自噬。在溶液中不稳定，请现配现用！此产品为危化品（急性毒性/易燃/皮肤腐蚀），请在穿戴防护面罩、防护手套和防护服后使用。 已取得危险化学品经营许可
Cycloheximide Chemical Structure
CAS: 66-81-9
客户使用Selleck的Cycloheximide发表文献268篇
产品质控
批次：
S741804
DMSO]
56 mg/mL]
false]
Ethanol]
56 mg/mL]
false]
Water]
15 mg/mL]
false
纯度：
99%
99
Cycloheximide相关产品
Fungal抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| MCF7 | Function assay | 10 ug/mL | 1 hr | Inhibition of HIF1alpha RNA translation in human MCF7 cells at 10 ug/mL pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis | 22607231 |
| AGS | Apoptosis assay | 150 ug/mL | 48 hrs | Induction of apoptosis in human AGS cells assessed as early apoptosis level at 150 ug/mL after 48 hrs by Annexin V-FITC apoptosis assay | 21899268 |
| T47D | Function assay | 10 uM | 4 hrs | Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting | 15974627 |
| T47D | Function assay | 0.3 uM | 4 hrs | Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting | 15974627 |
| T47D | Function assay | 3 uM | 16 hrs | Inhibition of hypoxia-induced HIF1 activation in human T47D cells at 3 uM after 16 hrs by luciferase reporter gene assay | 15974627 |
| T47D | Function assay | 0.7 uM | 16 hrs | Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells at 0.7 uM after 16 hrs by luciferase reporter gene assay | 15974627 |
| T47D | Function assay | 10 uM | 16 hrs | Inhibition of hypoxia-induced VEGF expression in human T47D cells at 10 uM after 16 hrs by ELISA | 15974627 |
| T47D | Function assay | 0.3 uM | 4 hrs | Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting | 15974627 |
| T47D | Function assay | 10 uM | 4 hrs | Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting | 15974627 |
| HEK293T | Function assay | 50 uM | 30 mins | Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 50 uM after 30 mins by spectrophotometry | 20118940 |
| T47D | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human T47D cells at 10 uM after 48 hrs by SRB assay | 23434131 |
| MDA-MB-231 | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay | 23434131 |
| NCI-H460 | Function assay | 10 ug/mL | up to 9 hrs | Reduction of HSP1 stability in human NCI-H460 cells assessed as protein degradation at 10 ug/mL up to 9 hrs by Western blot analysis | 24746225 |
| HeLa | Cytotoxicity assay | 25 uM | 18 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay | 25028062 |
| RAW264.7 | Function assay | 70 uM | 6 hrs | Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 70 uM after 6 hrs by luciferase reporter gene assay | 25667960 |
| HepG2-A16-CD81 | Function assay | 10 uM | NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration, IC50 = 0.0781 μM. | 22096101 | |
| neural precursor cells | Function assay | 3 uM | Induction of neurosphere phenotype changes in mouse neural precursor cells at 3 uM | 17417631 | |
| Jurkat T-cells | Function assay | 48 hours | Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.93 μM. | 11052798 | |
| Jurkat T-cells | Function assay | 48 hours | Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC80 = 1.54 μM. | 11052798 | |
| HeLa | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HeLa cells after 24 hrs, CD50 = 0.1 μM. | 18394884 | |
| 3T3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.912 μM. | 18771242 | |
| HeLa | Function assay | 2 hrs | Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5325 μM. | 20118940 | |
| HeLa | Function assay | 2 hrs | Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 2.8801 μM. | 20118940 | |
| 3T3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. | 20356064 | |
| BESM | Function assay | 88 hrs | Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50 = 0.4 μM. | 20547819 | |
| NIH/3T3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay, IC50 = 1.1 μM. | 21899268 | |
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 1.2 μM. | 21899268 | |
| AGS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human AGS cells after 48 hrs by MTT assay, IC50 = 3.6 μM. | 21899268 | |
| HT-29 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 12.8 μM. | 21899268 | |
| 3T3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. | 22437110 | |
| PA1 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. | 23202484 | |
| PA1 | Growth inhibition assay | 24 hrs | Growth inhibition of human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. | 28011220 | |
| CEM | Cytotoxicity assay | 5 days | Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay, IC50 = 0.2 μM. | 29778528 | |
| Vero | Cytotoxicity assay | 3 days | Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay, IC50 = 0.2 μM. | 29778528 | |
| 3T3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against rat 3T3 cells after 48 hrs by MTT assay, IC50 = 0.61 μM. | 30146096 | |
| CEM | Anticancer assay | Tested in vitro for anticancer activity against CEM cells, IC50 = 0.12 μM. | 10072683 | ||
| 9L | Anticancer assay | Tested in vitro for anticancer activity against 9L cells, IC50 = 0.2 μM. | 10072683 | ||
| SK-MEL-28 | Anticancer assay | Tested in vitro for anticancer activity against SK-MEL-28 cells, IC50 = 1 μM. | 10072683 | ||
| Vero | Cytotoxicity assay | Tested in vitro for cytotoxicity against Vero cells, IC50 = 1.2 μM. | 10072683 | ||
| LNCaP | Anticancer assay | Tested in vitro for anticancer activity against LNCaP cells, IC50 = 1.2 μM. | 10072683 | ||
| MCF-7 | Anticancer assay | Tested in vitro for anticancer activity against MCF-7 cells, IC50 = 1.5 μM. | 10072683 | ||
| PBM | Cytotoxicity assay | Tested in vitro for cytotoxicity against PBM cells, IC50 = 2.1 μM. | 10072683 | ||
| HepG2 | Anticancer assay | Tested in vitro for anticancer activity against HepG2 cells, IC50 = 2.5 μM. | 10072683 | ||
| SK-MES-1 | Anticancer assay | Tested in vitro for anticancer activity against SK-MES-1 cells, IC50 = 2.7 μM. | 10072683 | ||
| PC-3 | Anticancer assay | Tested in vitro for anticancer activity against PC-3 cells, IC50 = 3.5 μM. | 10072683 | ||
| Jurkat T-cells | Function assay | Inhibitory concentration against Human Jurkat T cells, IC50 = 0.93 μM. | 10212121 | ||
| Jurkat T-cells | Function assay | Inhibitory concentration against Human Jurkat T cells, IC80 = 1.54 μM. | 10212121 | ||
| CEM | Cytotoxicity assay | Cytotoxicity was determined in CEM cells, relative to RVT, IC50 = 0.08 μM. | 15081000 | ||
| PBM | Cytotoxicity assay | Cytotoxicity was determined in PBM cells, relative to RVT, IC50 = 0.46 μM. | 15081000 | ||
| Vero | Cytotoxicity assay | Cytotoxicity was determined in Vero cells, relative to RVT, IC50 = 0.53 μM. | 15081000 | ||
| HeLa | Function assay | Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay, IC50 = 0.036 μM. | 15974627 | ||
| medulloblastoma cells | Antiproliferative assay | Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay, EC50 = 0.042 μM. | 17417631 | ||
| neural precursor cells | Antiproliferative assay | Antiproliferative activity against mouse neural precursor cells by colony formation assay, EC50 = 0.054 μM. | 17417631 | ||
| astrocyte cells | Antiproliferative assay | Antiproliferative activity against mouse astrocyte cells by MTT assay, EC50 = 0.071 μM. | 17417631 | ||
| neural precursor cells | Antiproliferative assay | Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50 = 0.142 μM. | 17417631 | ||
| HepG2 | Function assay | HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 0.047 μM. | 22586124 | ||
| 3T3 | Cytotoxicity assay | Cytotoxicity against mouse 3T3 cells by SRB assay, IC50 = 0.3 μM. | 29247859 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 29435139 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis | 18066055 | ||
| HeLa | Function assay | Inhibition of mitosis in human HeLa cells by imaging analysis | 18066055 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Cycloheximide (NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80)，一种抗真菌抗生素，是一种真核生物蛋白质合成（protein synthesis）抑制剂，对体内蛋白质合（protein synthesis）和 RNA 合成（RNA synthesis）的 IC50 分别为 532.5 nM 和 2880 nM。Cycloheximide抑制铁死亡并抑制自噬。在溶液中不稳定，请现配现用！此产品为危化品（急性毒性/易燃/皮肤腐蚀），请在穿戴防护面罩、防护手套和防护服后使用。 |
|---|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03700788 | Not yet recruiting | Apical Periodontitis |
University of Southern California |
May 30 2023 | Phase 3 |
| NCT05506566 | Recruiting | Tumor|Positron-Emission Tomography |
First Affiliated Hospital of Fujian Medical University |
May 1 2022 | Phase 1|Phase 2 |
| NCT02202304 | Withdrawn | Periodontal Disease|Caries |
Rosa Moreno Lopez|Ivoclar Vivadent AG|University of Aberdeen |
September 10 2017 | Phase 4 |
| NCT01521325 | Completed | Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer |
Morphotek |
September 2011 | Phase 1 |
| NCT02168374 | Completed | Dental Caries |
Aline R F de Castilho|Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas Brazil |
March 2008 | Phase 2 |
化学信息&溶解度
| 分子量 | 281.35 | 分子式 | C15H23NO4 |
| CAS号 | 66-81-9 | SDF | -- |
| Smiles | CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C | ||
| 储存条件(自收到货起) | 3年 -20°C(避光) 粉状 |
此产品性质不稳定，需现配现用!建议您购买分装规格，或者在收到货后进行分装。 | |
|
体外溶解度 |
DMSO : 56 mg/mL ( (199.04 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 56 mg/mL Water : 15 mg/mL |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Cycloheximide | Cycloheximide supplier | purchase Cycloheximide | Cycloheximide cost | Cycloheximide manufacturer | order Cycloheximide | Cycloheximide distributor
